HIV/TB: When is it safe to start HAART? by Wood, R
S p r i n g  2 0 0 8                                                           T H E  S O U T H E R N  A F R I C A N  J O U R NA L  O F  H I V  M E D I C I N E       18
Tuberculous meningitis occurring in HIV-infected 
individuals (HIV/TBM) exemplifies the dilemmas facing 
clinicians when addressing potentially preventable 
mortality. HIV/TBM has a devastating clinical impact with 
a median time from onset of symptoms to presentation 
of 10 days, 67% mortality and a median time to death 
of 20 days.3 Expert opinion on when to start HAART in 
HIV-infected patients with TB meningitis varied between 
2 weeks and 12 months after starting TB medications.4 
This uncertainty of expert opinion reflects the present 
lack of randomised clinical trial data with which to 
inform clinical management. A clinical trial specifically 
addressing immediate initiation versus deferring HAART 
(zidovudine/lamivudine/efavirenz) for 8 weeks has been 
conducted at two hospital sites in Ho Chi Minh city, 
Vietnam. Results of this study should become available in 
late 2008 or early 2009.5 A study demonstrating proof of 
the concept that earlier initiation of antiretroviral therapy 
may impact on mortality of HIV patients with active 
opportunistic infections (OIs) was recently presented.6 
The AIDS Clinical Trials Group study 5164 (ACTG 5164) 
was a randomised strategy trial of immediate versus 
delayed ART in the setting of acute OI. At the time of 
inclusion study subjects had pneumocystis pneumonia 
(63%), cryptococcal meningitis (13%), other acute 
pneumonic illnesses (10%) or multiple opportunistic 
infections (30%). Patients were randomised to immediate 
or delayed initiation of HAART, a median of 12 days or 
45 days after starting OI treatment, respectively. After 
48 weeks, deaths in the early treatment group were 
significantly lower with no difference in drug toxicities, 
adherence or hospitalisation. Somewhat counter-
intuitively, IRD was also less frequent in the earlier 
treatment group. The conclusion from this study was 
that in the absence of contraindications very early use 
of HAART should be considered in patients with acute 
OIs. However, it should be noted that TB cases were not 
included in this study population.
CONSIDERATIONS DETERMINING EARLIER VERSUS 
LATER INITIATION OF HAART
The decision when to initiate HAART after TB treatment 
is complex, involving a number of variables including 
treatment tolerance, drug co-toxicities, pharmacokinetic 
drug interactions and impact of polypharmacy on 
adherence (Fig. 1). However, of over-riding importance 
is the mortality associated with delays in ART initiation 
versus mortality associated with IRD when HAART is 
initiated early. The frequency of IRD in cohort studies 
describing co-infected patients varies markedly between 
8% and 43%.7,8 The mean interval to IRD after HAART 
initiation also varies widely (1 - 180 days) with most cases 
occurring within the first 28 days.7 However, cross-cohort 
comparisons are complicated by differing mortality in 
cohorts from high- and low-resourced settings and 
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differing incidences of TB-associated IRD in TB patients 
starting HAART in different settings. Furthermore, 
while variable rates of IRD may represent differences 
between cohorts, analysis is complicated by variable 
ascertainment and lack of a standardised IRD definition. 
A consensus document with proposed definitions of 
IRD for use in resource-constrained settings may help 
address the problem of differing case definitions.8 IRD 
is characterised by worsening of systemic symptoms, 
transient enlargement of pre-existing lesions, onset of 
new lesions including lymphadenopathy, and worsening 
of radiographic changes. Life-threatening conditions 
are rare but include tracheal and bronchial obstruction, 
pulmonary adult respiratory distress syndrome (ARDS), 
central nervous system tuberculomas and cerebral 
oedema.7-13 The management of life-threatening IRD 
includes use of high-dose steroid therapy and may 
necessitate interruption of HAART, although there are 
no randomised controlled studies to inform policy. The 
precise pathological processes responsible for IRD are 
not clearly defined, but the condition is associated with 
an expansion of CD4 cells in the peripheral blood8,14 
and increased macrophage activity.15 Fig. 2 illustrates 
a proposal that clinical manifestations result from an 
interplay between cellular events and mycobacterial 
antigen load.16 The risk factors for development of IRD are 
predominantly a low CD4 cell count and a short interval 
between starting TB therapy and HAART initiation.9,13,17 
In a prospective Cape Town cohort, IRD occurred in 
100% and 70% of patients commencing HAART within 
30 days with CD4 counts of <50 cells/µl and 50 - 100 
cells/µl respectively13 (Fig. 3). Extrapulmonary TB and 
black ethnic group have been identified as additional 
risk factors for IRD.9 Severe TB-associated IRD therefore 
tends to develop in those patients who have a high 
mortality risk, manifested by low CD4 cell counts 
and a high mycobacterial burden associated with 
disseminated TB. Several studies reporting considerable 
morbidity associated with IRD have not shown an excess 
mortality.13,17-21 Similar findings were also reported in a 
South African cohort where 10.5% who developed TB-
IRD died; however, 9.9% of TB patients who did not 
develop IRD also died.9 Development of IRD and IRD-
associated mortality in these studies was therefore not 
associated with significant excess overall mortality.
Variations in IRD frequency and associated mortality 
indicate that the optimal timing of ART initiation may 
differ between settings. In lower income countries, 
the risk of mortality associated with delays in ART 
initiation is likely to outweigh the excess mortality of 
TB-associated IRD. The optimal timing of ART initiation 
may therefore be earlier in the course of TB treatment 
for patients in resource-limited settings compared with 
those in high-income settings. Current guidelines for the 
timing of HAART in patients with TB are shown in Table 
I.  All these guidelines reflect an increased urgency to 
commence HAART at lower CD4 cell counts with variable 
timing recommendations due to a lack of data from 
randomised controlled trials. This lack of informative 
data is clearly reflected in the recommendations of the 
International AIDS Society (IAS), USA.  Several guidelines 
focus on 8 weeks as a key time point in TB therapy when 
simplification of TB medications occurs. In South Africa 
schedule 1 TB therapy consists of an intensive four-
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Fig. 1. Factors influencing the decision of timing of 
commencement of HAART after starting TB therapy in HIV-
infected individuals.
Fig. 2. The proposed interaction between Mycobacterium 
tuberculosis antigen load and rate and intensity of immune 
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Fig. 3. The impact of baseline CD4 cell count and timing of 
initiation of HAART on risk of TB-immune recovery disease in 
the Gugulethu cohort, Cape Town (adapted from Lawn et al.13).
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drug therapy (isoniazid, rifampicin, pyrazinamide and 
ethambutol) which is reduced to two-drug maintenance 
(RIF/INH) after 8 weeks.22 The South African TB control 
programme promotes use of fixed-dose combination 
tablets which results in identical pill burdens before and 
after the 8-week treatment time point.  Rifampicin, the 
anti-TB agent with the greatest potential for drug-drug 
interactions with non-nucleoside and protease inhibitor 
antiretrovirals, is continued throughout the whole 6 
months of treatment. Similarly isoniazid, with a potential 
for peripheral neuropathy co-toxicity with stavudine, is 
also continued throughout TB therapy. The main co-
toxicity shared between TB and HAART is hepatotoxicity, 
and some staggering of initiation of the two treatment 
regimens may simplify clinical management of drug-
induced hepatitis. Although pyrazinamide, which is 
routinely discontinued after 8 weeks of TB treatment, 
may contribute somewhat to hepatic co-toxicity, it is 
unproven whether the optimal deferring time period is 
8 weeks,
STUDY DATA ADDRESSING WHEN TO START HAART
Randomised controlled trials addressing the optimal 
timing of ART initiation in patients with TB are awaited, 
but meanwhile data from observational cohorts and 
modelling studies may help inform policy. Cohort studies 
have reported a markedly variable impact of HAART on TB 
mortality.19,23-26 Three cohort studies describing outcomes 
in patients starting HAART at different time points after 
TB therapy reported at the International AIDS Society 
2008 Conference meeting in August 2008 highlight the 
difficulties in interpreting cohort data. A Brazilian clinic-
based cohort study of 662 patients found no significant 
difference in survival between patients starting HAART 
in the first 2 months, 2 - 6 months or more than 6 
months after commencement of TB treatment.24 In 
contrast, an Iranian study of 69 hospitalised patients 
showed significant increases in TB cure rate and survival 
in patients who started HAART within 2 weeks compared 
with 8 weeks of TB treatment.25 A third study, from 
Argentina, showed similar differences in TB cure rate and 
survival with early initiation of HAART.26 However, this 
last study also reported significant differences in baseline 
characteristics between the groups, demonstrating that 
cohort studies may be subject to considerable selection 
bias. A South African cohort study of the International 
Epidemiological Databases to Evaluate AIDS Group 
(IeDEA) retrospective analysis of 4 000 HIV/TB patients 
from multiple sites in the Free State and Cape Town 
will be completed and is planned for reporting during 
2009.27 
A decision analysis model, based on published cohort 
data, examined three treatment strategies in patients 
with AIDS and TB; early initiation of HAART (<2 months), 
deferred HAART (>2 months), and no HAART strategy.28 
The model indicated that earlier HAART could reduce 
mortality at 1 year by 30% and 80% compared with the 
deferred and no HAART strategies, respectively.
Several randomised controlled studies addressing 
the timing of HAART after starting TB treatment are 
currently enrolling.5,29-32 Of these ongoing studies only 
Year Organisation CD4 count Recommendations
2003 American Thoracic Society* CD4 <350 
CD4 >350




             Defer 4 - 8 wks
2004 WHO ‘Scaling up ART
in resource-limited settings’‡
CD4 <200  
CD4 200 - 350
CD4 >350
2 wks - 8 wks 
Start at 2mo.
Defer HAART





2 wks - 8 wks
8 wks
6 mo.
2006 IAS/USA panel¶                                           Individualise as there are no RCTs
2008 DHHS: Guidelines** CD4 <100 
CD4 100 - 200





8 - 24 wks or defer
Guidelines available at: *http://www.thoracic.org; †htpp://www.cdc.gov/mmwr/; ‡http://www.doh.gov.za; §http:// www.iasusa.org/pub/; ¶http:// www.aidsinfo.nih.gov/
Guidelines/; **http://www.who.int/3BYS/publications/documents/ARV_guidelines/en/
TABLE I. CURRENT INTERNATIONAL AND SOUTH AFRICAN GUIDELINES FOR THE TIMING OF INITIATION OF 
HAART IN HIV-INFECTED pATIENTS ON TB THERApY
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the Vietnamese TB meningitis study is expected to 
be able to report outcomes in the near future (Table 
II). The Cambodian Early versus Late Introduction of 
Antiretrovirals (CAMELIA), a large randomised open-
labelled study conducted in five sites in Cambodia, should 
be the first of these studies to report outcomes, some 
time during 2009 or 2010.29  Unexpectedly, preliminary 
data from the Starting Antiretroviral therapy in three 
Time Points in Tuberculosis (SAPIT) study conducted in 
KwaZulu-Natal became available in September 2008 
owing to the data safety and monitoring board (DSMB) 
discontinuing the third randomisation arm of the study 
because of a 55% increased  mortality in subjects 
deferring HAART for 6 - 8 months.31 
DISCUSSION
Determination of the optimal timing of initiation of ART 
in patients with TB is urgently needed in South Africa, 
where HIV/TB is extremely common and availability of 
HAART is rapidly expanding. HIV/TB case fatality rates 
are high and the optimal deferral time will therefore 
be determined predominantly by mortality rather 
than morbidity. Unfortunately the results of several 
randomised controlled trials addressing when to start 
HAART in TB, with a primary endpoint of survival, will 
not be available until 2009/2010. Meanwhile, preliminary 
data from the SAPIT study indicate that deferring 
treatment for 6 months is associated with significantly 
increased mortality.31 The Vietnamese study results of 
immediate initiation of HAART in TBM should become 
available in the next few months.5 The results of this 
study may not necessarily be generalisable to other 
forms of TB; however, any significant mortality benefit 
of immediate initiation of HAART will bolster support for 
earlier treatment in other severe forms of TB. 
The present status of information concerning the most 
important factors that may impact on the optimal timing 
of HAART in TB are shown in Fig. 4. Reduction of ongoing 
HIV-related mortality by HAART is counterbalanced by TB/
IRD-associated mortality and a clinical need to stagger 
the initiation of both treatments for ease of clinical 
management of co-toxicity. Those at highest risk of HIV 
progression also have the highest risk of co-toxicity and 
IRD. The ACTG 5164 study has demonstrated improved 
survival with very early initiation of HAART in patients 
co-infected with acute OIs.6 Treatment of TB requires 
prolonged treatment and is complicated by frequent 
occurrence of IRD. However, published reports indicate 
that while TB/IRD is a common cause of morbidity it is a 
less frequent cause of death.
Much interest has rightly focused on the optimal 
timing of HAART in relation to TB treatment. In low-
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Fig. 4. Data from present and future studies that affect 
the timing of initiation of HAART and are likely to impact 
on preventable HIV mortality in individuals already on TB 
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diagnosed after prolonged delay, and yet the mortality 
associated with even short delays in accessing HAART 
is unacceptably high. Furthermore, the potentially more 
important problem of delays in the care pathway has 
received little attention.
While the results of randomised controlled studies 
addressing the timing of initiation of HAART are eagerly 
awaited, the results may still not be generalisable to all 
types of TB, HIV progression, race and health systems. 
In the meantime it is important to recognise that time 
delays between the onset of TB symptoms and starting 
HAART in those eligible for HAART are associated with 
potentially preventable HIV-related mortality and that 
all delays should be minimised. 
REFERENCES
  1. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2008. 
Geneva: World Health Organization, 2008. 
  2. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV 
prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152. 
  3. Torok ME, Chau TTH, Mai PP, et al. PlosONE 2008; 3(3): e1772
  4. Torok ME, Day JN, Hien TT, Farrar JJ. Immediate or deferred antiretroviral therapy for 
central nervous system opportunistic infections? AIDS 2005; 19(5): 535-536.
  5. Immediate versus deferred antiretroviral therapy for HIV-associated tuberculous 
meningitis. http://clinicaltrials.gov/ct2/show/NCT00433719 (accessed 24 November 
2008).
  6. Zolopa A, Andersen J, Komarow L, et al. Immediate vs deferred ART in the setting of 
acute AIDS-related opportunistic infection: Final results of a randomized strategy 
trial, ACTG A5164. 15th Conference on Retroviruses and Opportunistic Infections, 
25 - 28 February 2008, Boston, MA, USA. Oral abstract 142.
  7. Lawn SD, Bekker L-G, Wood R. How effectively does antiretroviral treatment of 
HIV restore immune responses to Mycobacterium tuberculosis? Implications for 
tuberculosis control. (Review). AIDS 2005; 19(11): 1113-1124.
  8. Meintjes G, Lawn SD, Scano F, et al.; International Network for the Study of HIV-
associated IRIS. Tuberculosis-associated immune reconstitution inflammatory 
syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 
2008; 8(8): 516-523. 
  9. Burman W, Weis S, Vernon A, et al. Frequency, severity and duration of immune 
reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 2007; 11(12): 
1282-1289.
10. Buckingham SJ, Haddow LJ, Shaw PJ, Miller RF. Immune reconstitution inflammatory 
syndrome in HIV-infected patients with mycobacterial infections starting highly 
active anti-retroviral therapy. Clin Radiol 2004; 59(6): 505-513.
11. Goldsack NR, Allen S, Lipman MC. Adult respiratory distress syndrome as a severe 
immune reconstitution disease following the commencement of highly active 
antiretroviral therapy. Sex Transm Infect 2003; 79(4): 337-338.
12. Dautremer J, Pacanowski J, Girard PM, Lalande V, Sivignon F, Meynard JL. A 
new presentation of immune reconstitution inflammatory syndrome followed 
by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous 
meningitis. AIDS 2007; 21(3): 381-382.
13. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution 
disease: incidence, risk factors and impact in an antiretroviral treatment service in 
South Africa. AIDS 2007; 21(3): 335-341.
14. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-
responses induces immune restoration syndrome in tuberculosis and HIV co-
infected patients. AIDS 2006; 20(2): F1-7.
15. Lawn SD, Wainwright H, Orrell C. Fatal unmasking tuberculosis immune 
reconstitution disease with bronchiolitis obliterans organizing pneumonia: role of 
macrophages. AIDS (in press).
16. Lawn SD, Wilkinson RJ, Lipman MCI, Wood R. Immune reconstitution and 
‘unmasking’ of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 
2008; 177(7): 680-685.
17. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune 
reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients 
receiving antituberculous and antiretroviral therapy. J Infect 2006; 53(6): 357-363. 
18. Tansuphasawadikul S, Saito W, Kim J, et al. Southeast Asian J Trop Med Pub Health 
2007; 38(6): 1053-1060.
19. Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV-infected 
tuberculosis patients saves lives but needs to be used more frequently in Thailand. 
J Acquir Immune Defic Syndr 2008; 48(2): 181-189. 
20. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Vibhagool A. Initiation 
of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical 
experiences from Thailand. J Infect 2006; 52(3): 188-194.
21. Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy 
during tuberculosis treatment and marked reduction in death rate of HIV-infected 
patients, Thailand. Emerg Infect Dis 2007; 13(7): 1001-1007.
22. South African National Tuberculosis Control Programme Practical Guidelines. 
Department of Health, 2004. www.doh.gov.za (accessed 24 November 2008). 
23. Zacharia R, Fitzgerald M, Massaquoi M, et al. Does antiretroviral treatment reduce 
case fatality among HIV-patients with tuberculosis in Malawi? Int J Tuberc Lung Dis 
2007; 11(8): 848-853.  
24. Saraceni V, King  BS, Pacheco AGF, Golub JE, Cavalcante SC,  Tuberculosis, HAART 
use and survival in the THRio Cohort, Rio de Janeiro, Brazil. AIDS 2008 – XVII 
International AIDS Conference, Mexico City, 3 - 8 August 2008. Abstract No. 
MOAB0305. 
25. Tabarsi P, Tehrani A, Baghaei P, Mansouri D, Masjedi M, Altice F. Early initiation of 
antiretroviral therapy results in decreased morbidity and mortality am. AIDS 2008 
– XVII International AIDS Conference, Mexico City, 3 - 8 August 2008. Abstract No. 
MOPDB205. 
26. Toibaro JJ, Warley E, Bruguera JM, Tamayo Antabak N, Contarelli J. Early versus 
late cART treatment in HIV/TB co-infected patients in Argentina. AIDS 2008 – XVII 
International AIDS Conference, Mexico City, 3 - 8 August 2008. Abstract No. 
MOPDB206.
27. Exploring when to start antiretrovirals in patients already on treatment for 
tuberculosis. www.iedea-sa.org (accessed 24 November 2008). 
28. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis 
patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44(2): 
229-234.
29.  The Cambodian Early versus Late Introduction of Antiretrovirals (CAMELIA) study. 
www.cambodianhealthcommittee.org/news_hivtb.html (accessed 24 November 
2008). 
30. Randomized controlled trial to determine the optimal timing for HAART initation 
among HIV-TB co-infection. ACTG 5221. www.cidrz.org/projects/actg_5221 
(accessed 24 November 2008). 
31. Starting Antiretroviral therapy in three Time Points in Tuberculosis (SAPIT). www.
caprisa.org (accessed 24 November 2008). 
32. TB-HAART STUDY. An evaluation of the impact of early initiation of HAART on 
TB treatment. www.who.int/tdr/publications/tdrnews/pdf/TDRnews-issue-78.pdf 
(accessed 24 November 2008). 
HIV-TB.indd   24 12/17/08   3:18:00 PM
